Cancer immunotherapies and predictive biomarkers company Jounce Therapeutics has agreed to be acquired by Concentra Biosciences for $1.85 in cash per share plus 27 March 2023
Germany’s Merck KGaA has regained exclusive worldwide rights to develop, manufacture, and commercialize its checkpoint blocker Bavencio (avelumab). 27 March 2023
An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's newly-announced $43 billion takeover of Seagen. 13 March 2023
The strategic venture capital unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has put its weight behind a $100 million boost for a new precision medic 8 March 2023
A merger between Flamingo Therapeutics and Dynacure will create a new oncology company, retaining the Flamingo name, advancing lead candidates danvatirsen and F 3 March 2023
If January offered excitement, promise and hope for a busy year of pharma M&A ahead, then February has more than tempered those expectations. 2 March 2023
The Dutch business of Rhythm Pharmaceuticals has acquired Xinvento, a Netherlands-based biotech focused on therapies for congenital hyperinsulinism (CHI). 27 February 2023
Struggling to finance further development of its immunotherapy candidates alone, Jounce Therapeutics has announced plans to merge with British firm Redx Pharma 23 February 2023